1700012B07Rik Activators are a collection of chemical compounds that indirectly promote the functional activity of 1700012B07Rik through manipulation of distinct cellular signaling pathways. Compounds like Forskolin and Ionomycin achieve this by increasing intracellular cAMP and calcium levels, respectively, which activates protein kinase A and other calcium-dependent signaling mechanisms that can phosphorylate substrates and regulators within the functional sphere of 1700012B07Rik, potentially enhancing its activity. Similarly, Genistein's inhibition of tyrosine kinases and the PI3K inhibitors LY294002 and Wortmannin's suppression of PI3 kinase activity shift cellular signaling away from pathways that might compete withthose involving 1700012B07Rik, thereby indirectly amplifying the protein's role. PMA, a potent activator of protein kinase C (PKC), could further enhance the activity of 1700012B07Rik by phosphorylating intermediates in pathways where 1700012B07Rik is a key player, while Sphingosine-1-phosphate signals through G-protein-coupled receptors to activate downstream pathways that intersect with those regulated by 1700012B07Rik, potentially leading to increased activity of the protein.
In a complementary manner, compounds like A23187 (Calcimycin) and Thapsigargin disrupt calcium homeostasis, which can selectively enhance pathways crucial to 1700012B07Rik's function. MAPK signaling modulators such as U0126 and SB203580 act as inhibitors of MEK1/2 and p38 MAPK, respectively. These actions can redirect signaling to favor the enhancement of 1700012B07Rik's activity by reducing the activity of these MAPKs, which might otherwise suppress pathways where 1700012B07Rik is essential. Additionally, Epigallocatechin gallate (EGCG), through its broad kinase inhibitory effects, can indirectly promote the activity of 1700012B07Rik by lifting competitive inhibition on pathways in which 1700012B07Rik is involved. Collectively, these activators, through their targeted effects on various signaling cascades, facilitate the enhancement of 1700012B07Rik's functional activity without necessitating increased expression or direct activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate interacts with its receptors to activate G-protein-coupled receptor signaling, which can lead to downstream effects on phospholipase C and PI3K pathways, thereby impacting processes where 1700012B07Rik is functionally involved. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC), which then may phosphorylate substrates and regulators in pathways wherein 1700012B07Rik is active, potentially enhancing the protein's functional activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin increases intracellular calcium levels, which may activate calcium-dependent signaling pathways crucial for cellular processes that involve 1700012B07Rik, possibly resulting in the enhancement of its activity. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as an ionophore that increases intracellular calcium levels. This rise in calcium can activate pathways that are essential for cellular functions regulated by 1700012B07Rik, indirectly enhancing its activity. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can reduce competitive signaling through tyrosine kinases, potentially allowing pathways where 1700012B07Rik is involved to be more active by reducing this competition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can shift signaling pathways towards those in which 1700012B07Rik is involved, by decreasing PI3 kinase activity and subsequent AKT signaling, which might otherwise suppress these pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could modulate cellular stress responses, potentially leading to the enhancement of pathways where 1700012B07Rik is active by reducing p38 MAPK-mediated suppression of these pathways. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to increased cytosolic calcium levels, which can activate calcium-dependent signaling pathways potentially enhancing the activity of 1700012B07Rik. | ||||||